Redx Pharma plc has described discoidin domain-containing receptor 1 (DDR1) and/or discoidin domain-containing receptor 2 (DDR2) inhibitors reported to be useful for the treatment of cardiovascular, renal, inflammatory disorders, liver diseases, fibrosis, transplant rejection and cancer.
Jacobio Pharmaceuticals Co. Ltd. has divulged cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified sodium channel protein type 10 subunit α (Nav1.8) channel blockers reported to be useful for the treatment of treatment of pain, Charcot-Marie-Tooth disease, urinary incontinence, multiple sclerosis and arrhythmia.
Erasca Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS G12D mutant targeting moiety through a linker reported to be useful for the treatment of cancer.
In efforts to design microtubule polymerization inhibitors with the ability to induce immunogenic cell death (ICD), investigators from China Pharmaceutical University have discovered novel isoquinoline analogues based on podophyllotoxin and diphyllin that act as dual tubulin polymerization and V-ATPase inhibitors.
Samsung Life Science Fund, created jointly between Samsung Biologics Co. Ltd., Samsung Bioepis Co. Ltd. and Samsung C&T, and managed by Samsung Venture Investment Corp., and Brickbio Inc. have announced Samsung’s investment in preclinical-stage biopharmaceutical company Brickbio.
CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2039, a highly selective methionine adenosyltransferase 2A (MAT2A) inhibitor, for advanced malignant tumors.
Researchers from the University of Illinois at Chicago and University of Arizona presented the discovery and preclinical evaluation of a novel BD1-selective BET inhibitor, XL-126, being developed as a potential anti-inflammatory agent.
For the treatment of HIV infection, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used to prevent viral replication by binding to a pocket near the polymerase active site of HIV-1 reverse transcriptase.
RSS
